Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1463388

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1463388

Global Mycoplasma Testing Market Size, Share, Growth Analysis, By Application(Cell Line Testing, Virus Testing), By End-Use(Academic Research Institutes, Cell Banks) - Industry Forecast 2024-2031

PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Mycoplasma Testing Market size was valued at USD 298.91 million in 2022 and is poised to grow from USD 340.76 million in 2023 to USD 972.04 million by 2031, growing at a CAGR of 14% during the forecast period (2024-2031).

Providing dependable, accurate, and effective instruments and services for identifying and averting Mycoplasma contamination in many contexts is the aim of the mycoplasma testing market. The market includes a wide range of goods, such as instruments, software, reagents, kits, and testing, in addition to laboratory services including consulting, testing, and validation. Numerous industries, including biotechnology, pharmaceuticals, academic research, and clinical diagnostics, are served by the mycoplasma testing market. The market for mycoplasma testing is propelled by multiple causes, such as the escalating need for cell-based therapies and biopharmaceuticals, the expanding consciousness about the potential hazards and repercussions of mycoplasma contamination, and the introduction of sophisticated technologies and platforms for mycoplasma testing. Furthermore, there is a growing need for more reliable and effective testing solutions due to the tightening and standardization of regulatory criteria and norms around mycoplasma testing. The market for mycoplasma testing is also constrained by a number of variables, including the high price of testing goods and services, the lack of harmonization and consistency in testing protocols, and the scarcity of infrastructure and qualified labor for mycoplasma testing. The market for mycoplasma testing also has to contend with a number of obstacles, including the requirement for ongoing innovation and enhancement of testing goods and services in order to meet changing consumer and regulatory demands. Additionally, the market must deal with the problems of cross-reactivity with other pollutants, false-positive and false-negative results, and the possibility of genetic variability and adaptation of mycoplasma strains.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mycoplasma Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mycoplasma Testing Market Segmental Analysis

The global mycoplasma testing market is segmented on the application, end-use and region. By application, the market is segmented into cell line testing, virus testing, end of production cells testing, others. By end-use, the market is segmented into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Mycoplasma Testing Market

The market for Mycoplasma testing is being driven by the increasing need for cell-based treatments and biopharmaceuticals. To guarantee the safety and effectiveness of these products and therapies, premium cells free of Mycoplasma contamination are needed.

Restraints in the Global Mycoplasma Testing Market

Many clients may find the high expense of mycoplasma testing goods and services to be a major deterrent, particularly in developing nations or environments with limited resources. The type of test utilized, the sample's complexity, and the test's sensitivity and specificity can all affect how much a mycoplasma test costs. Certain sophisticated testing techniques, such high-throughput sequencing or PCR-based assays, can be quite costly, rendering them unaffordable for certain clients.

Market Trends of the Global Mycoplasma Testing Market

Modern platforms and technologies, like PCR-based assays, flow cytometry, and nucleic acid sequencing, are emerging in the mycoplasma testing sector. These tools provide improved speed, sensitivity, and specificity over the conventional culture-based approaches.

Product Code: SQMIG35I2219

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Mycoplasma Testing Market by Application

  • Market Overview
  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • and Others

Global Mycoplasma Testing Market by End-Use

  • Market Overview
  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • and Others

Global Mycoplasma Testing Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza Group Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sartorius AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PromoCell GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • American Type Culture Collection (ATCC) (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bionique Testing Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biological Industries Israel Beit Haemek Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Charles River Laboratories International, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Bioarray (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • InvivoGen (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Minerva Biolabs GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biological Industries US, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Norgen Biotek Corp. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novacyt Group (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mycoplasma Experience (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genscript Biotech Corporation (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneCopoeia, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jena Bioscience GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!